{"id":62,"date":"2014-02-12T11:28:30","date_gmt":"2014-02-12T13:28:30","guid":{"rendered":"http:\/\/sites.usp.brretrovirus\/?page_id=62"},"modified":"2015-03-12T14:32:25","modified_gmt":"2015-03-12T16:32:25","slug":"objetivos","status":"publish","type":"page","link":"https:\/\/sites.usp.br\/retrovirus\/objetivos\/","title":{"rendered":"Objetivos"},"content":{"rendered":"<p>O NAP \u2013 Retrov\u00edrus USP atuar\u00e1 em 3 vertentes de trabalho principais: HIV, HTLV e Retrovirologia B\u00e1sica:<\/p>\n<p>Na \u00e1rea de HIV:<\/p>\n<p>1-\u00a0\u00a0\u00a0\u00a0\u00a0 Co-morbidades: Altera\u00e7\u00f5es cognitivas associadas ao HIV<\/p>\n<p>2-\u00a0\u00a0\u00a0\u00a0\u00a0 Co-infec\u00e7\u00f5es com v\u00edrus da hepatite C (HCV); Poliomav\u00edrus (JCV e BK) e HTLV.<\/p>\n<p>3-\u00a0\u00a0\u00a0\u00a0\u00a0 Neoplasias \u2013 Linfoma e v\u00edrus papiloma humano (HPV);.<\/p>\n<p>4-\u00a0\u00a0\u00a0\u00a0\u00a0 Resist\u00eancia gen\u00e9tica e genot\u00edpica aos anti-retrovirais.<\/p>\n<p>5-\u00a0\u00a0\u00a0\u00a0\u00a0 Ades\u00e3o aos antirretrovirais (ARTs).<\/p>\n<p>6-\u00a0\u00a0\u00a0\u00a0\u00a0 Aspectos psicol\u00f3gicos envolvidos nos pacientes infectados pelo HIV e seus parceiros.<\/p>\n<p>7-\u00a0\u00a0\u00a0\u00a0\u00a0 Altera\u00e7\u00f5es metab\u00f3licas, nutricionais, risco cardio-vascular e metabolismo \u00f3sseo.<\/p>\n<p>8-\u00a0\u00a0\u00a0\u00a0\u00a0 Acessibilidade e Reabilita\u00e7\u00e3o de sequelas decorrentes das co-morbidades.<\/p>\n<p>Na \u00e1rea de HTLV:<\/p>\n<p>1-\u00a0\u00a0\u00a0\u00a0\u00a0 Diagn\u00f3stico sorol\u00f3gico e molecular: ELISA , PCR convencional e PCR em tempo real .<\/p>\n<p>2-\u00a0\u00a0\u00a0\u00a0\u00a0 Co-morbidades: altera\u00e7\u00f5es odontol\u00f3gicas; dermatol\u00f3gicas e neurol\u00f3gicas, em especial na s\u00edndrome cl\u00ednica intermedi\u00e1ria (oligo-sintom\u00e1ticos), al\u00e9m da HAM\/TSP e ATLL.<\/p>\n<p>3-\u00a0\u00a0\u00a0\u00a0\u00a0 Carga proviral do HTLV-1 \u00a0como marcador progn\u00f3stico e diagn\u00f3stico; Marcadores imunes, como\u00a0 linfoprolifera\u00e7\u00e3o.<\/p>\n<p>4-\u00a0\u00a0\u00a0\u00a0\u00a0 Tratamento convencional e novas estrat\u00e9gias contra a mielopatia associada ao HTLV-1.<\/p>\n<p>5-\u00a0\u00a0\u00a0\u00a0\u00a0 Preven\u00e7\u00e3o da infec\u00e7\u00e3o materno-infantil e horizontal;<\/p>\n<p>6-\u00a0\u00a0\u00a0\u00a0\u00a0 Reabilita\u00e7\u00e3o e Acessibilidade: papel da fisioterapia e terapia ocupacional nos casos com HAM\/TSP.<\/p>\n<p>7-\u00a0\u00a0\u00a0\u00a0\u00a0 Aspectos psico-sociais envolvidos no contexto da infec\u00e7\u00e3o pelo HTLV.<\/p>\n<p>Na \u00e1rea de Retrovirologia B\u00e1sica:<\/p>\n<p>1-\u00a0\u00a0\u00a0\u00a0\u00a0 Diversidade gen\u00e9tica dos retrov\u00edrus humanos e de primatas n\u00e3o-humanos.<\/p>\n<p>2-\u00a0\u00a0\u00a0\u00a0\u00a0 Origem e diversidade do HTLV-1, HTLV-2 e STLV-1;<\/p>\n<p>3-\u00a0\u00a0\u00a0\u00a0\u00a0 Desenvolvimento de m\u00e9todos sens\u00edveis de detec\u00e7\u00e3o da express\u00e3o de Retrov\u00edrus end\u00f3genos.<\/p>\n<p>4-\u00a0\u00a0\u00a0\u00a0\u00a0 Detec\u00e7\u00e3o de transcritos de Retrov\u00edrus end\u00f3genos como bio-marcadores de progress\u00e3o de doen\u00e7as como, por exemplo, aids e esclerose m\u00faltipla.<\/p>\n<p>5-\u00a0\u00a0\u00a0\u00a0\u00a0 Mecanismos de transativa\u00e7\u00e3o: Intera\u00e7\u00e3o entre retrov\u00edrus end\u00f3genos e ex\u00f3genos e v\u00edrus de DNA e RNA.<\/p>\n<p>6-\u00a0\u00a0\u00a0\u00a0\u00a0 Investiga\u00e7\u00e3o da influ\u00eancia da atividade de Retrov\u00edrus End\u00f3genos na reposta imune do hospedeiro.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>O NAP \u2013 Retrov\u00edrus USP atuar\u00e1 em 3 vertentes de trabalho principais: HIV, HTLV e Retrovirologia B\u00e1sica: Na \u00e1rea de HIV: 1-\u00a0\u00a0\u00a0\u00a0\u00a0 Co-morbidades: Altera\u00e7\u00f5es cognitivas associadas ao HIV 2-\u00a0\u00a0\u00a0\u00a0\u00a0 Co-infec\u00e7\u00f5es com v\u00edrus da hepatite C (HCV); Poliomav\u00edrus (JCV e BK) e HTLV. 3-\u00a0\u00a0\u00a0\u00a0\u00a0 Neoplasias \u2013 Linfoma e v\u00edrus papiloma humano (HPV);. 4-\u00a0\u00a0\u00a0\u00a0\u00a0 Resist\u00eancia gen\u00e9tica e [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-62","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/sites.usp.br\/retrovirus\/wp-json\/wp\/v2\/pages\/62","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sites.usp.br\/retrovirus\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sites.usp.br\/retrovirus\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sites.usp.br\/retrovirus\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.usp.br\/retrovirus\/wp-json\/wp\/v2\/comments?post=62"}],"version-history":[{"count":4,"href":"https:\/\/sites.usp.br\/retrovirus\/wp-json\/wp\/v2\/pages\/62\/revisions"}],"predecessor-version":[{"id":110,"href":"https:\/\/sites.usp.br\/retrovirus\/wp-json\/wp\/v2\/pages\/62\/revisions\/110"}],"wp:attachment":[{"href":"https:\/\/sites.usp.br\/retrovirus\/wp-json\/wp\/v2\/media?parent=62"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}